Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
- 1 November 1990
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 8 (11) , 1874-1879
- https://doi.org/10.1200/jco.1990.8.11.1874
Abstract
The disposition of total and non-protein-bound etoposide was investigated in 21 cancer patients receiving etoposide and cisplatin combination chemotherapy. Etoposide plasma concentrations were determined using a specific high-performance liquid chromatography (HPLC) method, and etoposide plasma protein binding was determined by equilibrium dialysis. The patients had a wide range of renal function (creatinine clearance, 32 to 159 mL/min/m2) and hepatic function (total bilirubin range, 0.3 to 21.5 mg/dL; aspartate aminotransferase [AST] range, 14 to 415 IU/L; serum albumin range, 2.7 to 4.1 g/dL). The mean etoposide total systemic clearance was not different in 15 patients with total bilirubin less than 1.0 mg/dL versus six patients with total bilirubin 1.1 to 21.5 mg/dL (18.7 +/- 5.9 mL/min/m2 v 26.4 +/- 10.7 mL/min/m2; t-test P = .06), with a trend toward higher total clearance in the patients with abnormal bilirubin values. However, the mean clearance of unbound etoposide was significantly lower in patients with increased total bilirubin (220 +/- 90 mL/min/m2 v 135 +/- 61 mL/min/m2; t-test P = .027). The fraction of etoposide unbound (fu) in plasma was significantly higher in patients with increased bilirubin (9% +/- 3% v 27% +/- 15%; t-test P = .002), explaining the trend toward higher total clearance in these patients. Etoposide clearance (total or unbound) in the 14 patients with measurable hepatic metastases was not different from the clearance in the seven patients without hepatic metastases. This study provides an explanation for why patients with increased bilirubin do not have lower total systemic clearance of etoposide, and indicates that such patients have a higher exposure to unbound etoposide. The results of ongoing pharmacodynamic studies of total and unbound etoposide in patients with increased bilirubin will determine the clinical relevance of altered etoposide protein binding.This publication has 6 references indexed in Scilit:
- Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variabilityClinical Pharmacology & Therapeutics, 1989
- PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF 72-HOUR CONTINUOUS INFUSION OF ETOPOSIDE IN PATIENTS WITH ADVANCED CANCER1987
- Etoposide pharmacokinetics in patients with normal and abnormal organ function.Journal of Clinical Oncology, 1986
- PHARMACOKINETICS OF ETOPOSIDE IN PATIENTS WITH ABNORMAL RENAL AND HEPATIC-FUNCTION1986
- High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical DetectionJournal of Pharmaceutical Sciences, 1984
- A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximationJournal of Pharmacokinetics and Biopharmaceutics, 1978